高压氧增敏脑转移瘤立体定向放射外科治疗:一项原理验证研究
38例患者中,19例脑转移瘤患者接受高压氧后立体定向放射外科治疗(25个病灶),19例历史对照(27个病灶)按组织学、GPA、切除状态和病灶大小匹配;高压氧舱至出束平均8.3±1.7分钟,两组不良事件相当,无III或IV级严重不良事件;局部控制、远处复发、放射性坏死和总生存无显著差异,1年估计生存率数值上倾向高压氧组。
要点
- 高压氧后立体定向放射外科治疗可行,未观察到放射性坏死或其他临床结局恶化。
- 高压氧组与对照组不良事件相当,无III或IV级严重不良事件。
- 1年放射性坏死无生存率高压氧组83% vs 对照组60%,局部复发无生存率95% vs 78%,均无统计学显著差异。
核心结论
- 脑转移瘤立体定向放射外科治疗前加用高压氧可行,未观察到放射性坏死和其他临床结局的明显下降。
研究设计与样本
- 研究纳入38例患者,19例脑转移瘤患者(25个病灶)在立体定向放射外科治疗前接受高压氧,19例历史对照(27个病灶)按组织学、GPA、切除状态和病灶大小匹配。
主要发现
- 高压氧舱至立体定向放射外科出束的平均时间为8.3±1.7分钟。
- 高压氧组与对照组的不良事件相当,未观察到III或IV级严重不良事件。
- Kaplan-Meier分析显示高压氧组与对照组的放射性坏死无生存率、全脑放疗前放射性坏死无生存率、全脑放疗前局部复发无生存率、全脑放疗前远处复发无生存率和总生存均无显著差异。
- 1年估计生存率数值上倾向立体定向放射外科联合高压氧组:放射性坏死无生存率83% vs 60%;全脑放疗前放射性坏死无生存率78% vs 60%;全脑放疗前局部复发无生存率95% vs 78%;全脑放疗前远处复发无生存率61% vs 57%;总生存率73% vs 56%。
- 多变量Cox模型显示高压氧治疗与放射性坏死、局部或远处复发或死亡风险无显著关联;但显示局部复发与较高体积、放射性坏死与肿瘤切除、总生存与切除、总生存与较高GPA有统计学显著关联(p < 0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Increased oxygen levels may enhance the radiosensitivity of brain metastases treated with stereotactic radiosurgery (SRS). This project administered hyperbaric oxygen (HBO) prior to SRS to assess feasibility, safety, and response. METHODS: 38 patients were studied, 19 with 25 brain metastases treated with HBO prior to SRS, and 19 historical controls with 27 metastases, matched for histology, GPA, resection status, and lesion size. Outcomes included time from HBO to SRS, quality-of-life (QOL) measures, local control, distant (brain) metastases, radionecrosis, and overall survival. RESULTS: The average time from HBO chamber to SRS beam-on was 8.3 ± 1.7 minutes. Solicited adverse events (AEs) were comparable between HBO and control patients; no grade III or IV serious AEs were observed. Radionecrosis-free survival (RNFS), radionecrosis-free survival before whole-brain radiation therapy (WBRT) (RNBWFS), local recurrence-free survival before WBRT (LRBWFS), distant recurrence-free survival before WBRT (DRBWFS), and overall survival (OS) were not significantly different for HBO patients and controls on Kaplan-Meier analysis, though at 1-year estimated survival rates trended in favor of SRS + HBO: RNFS - 83% vs 60%; RNBWFS - 78% vs 60%; LRBWFS - 95% vs 78%; DRBWFS - 61% vs 57%; and OS - 73% vs 56%. Multivariate Cox models indicated no significant association between HBO treatment and hazards of RN, local or distant recurrence, or mortality; however, these did show statistically significant associations (p < 0.05) for: local recurrence with higher volume, radionecrosis with tumor resection, overall survival with resection, and overall survival with higher GPA. CONCLUSION: Addition of HBO to SRS for brain metastases is feasible without evident decrement in radiation necrosis and other clinical outcomes.
引用
- Hartford AC, Gill GS, Ravi D, et al. Sensitizing brain metastases to stereotactic radiosurgery using hyperbaric oxygen: A proof-of-principle study. Radiother Oncol. 2022. PMID: 36404528. doi:10.1016/j.radonc.2022.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。